Last reviewed · How we verify
SPEVIGO (SPESOLIMAB-SBZO)
SPEVIGO (generic name: SPESOLIMAB-SBZO) is a Interleukin-36 Receptor Antagonist [EPC] drug developed by BOEHRINGER INGELHEIM PHARMACEUTICALS INC. It is currently FDA-approved for Erythrodermic psoriasis, Generalized pustular psoriasis, Pustular psoriasis.
Spevigo is a medication that targets the IL36 receptor, classified as an antagonist. It is used to treat conditions such as Generalized Pustular Psoriasis and Hidradenitis Suppurativa.
At a glance
| Generic name | SPESOLIMAB-SBZO |
|---|---|
| Sponsor | BOEHRINGER INGELHEIM PHARMACEUTICALS INC |
| Drug class | Interleukin-36 Receptor Antagonist [EPC] |
| Target | Interleukin-1 receptor-like 2 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Erythrodermic psoriasis
- Generalized pustular psoriasis
- Pustular psoriasis
Common side effects
- Diarrhea
- Otitis externa
- Infections (general)
- Vulvovaginal candidiasis
- Vulvovaginal mycotic infection
- Latent tuberculosis
- Gastritis
- Device-related infection
- Subcutaneous abscess
- Furuncle
- Influenza
Serious adverse events
- Serious infection (urinary tract infection)
- DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) - possible
Key clinical trials
- A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis (N/A)
- Effisayil® REP:An Open-label, Multicenter, Single-arm, Post-marketing Trial (in Select Countries) to Evaluate Efficacy and Safety and the Impact of Immunogenicity on Efficacy, Safety, and Pharmacokine (Phase 4)
- Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1. (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPEVIGO CI brief — competitive landscape report
- SPEVIGO updates RSS · CI watch RSS
- BOEHRINGER INGELHEIM PHARMACEUTICALS INC portfolio CI
Frequently asked questions about SPEVIGO
What is SPEVIGO?
What is SPEVIGO used for?
Who makes SPEVIGO?
What is the generic name of SPEVIGO?
What drug class is SPEVIGO in?
What development phase is SPEVIGO in?
What are the side effects of SPEVIGO?
What does SPEVIGO target?
Related
- Drug class: All Interleukin-36 Receptor Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-1 receptor-like 2
- Manufacturer: BOEHRINGER INGELHEIM PHARMACEUTICALS INC — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Erythrodermic psoriasis
- Indication: Drugs for Generalized pustular psoriasis
- Indication: Drugs for Pustular psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing